Prevalence of residual replication in HIV-1 patients on Tenofovir, Lamuvidine and Dolutegravir (TLD) treatment followed at Al-Nadjma Multipurpose Center from 2021 to 2023
Crossref DOI link: https://doi.org/10.53771/ijlsra.2024.6.1.0042
Published Online: 2024-03-30
Update policy: https://doi.org/10.53771/sra.ourcrossmarkpolicy
ASBAGUI FAYSALA Oscar,
NAIBI KEITOYO Amedé,
AHMAT MAHAMAT Ahmat,
DJELASSEM Franklin,
OUMAR ALKHATAD Djelani,
MAHO Foulzi,
ADAM IBRAHIM Bahar,
MAHAMAT-NOUR Aguid,
BARHIM BOY Otchom,
